GlassScriptPhysician profile
Oscar Soto
NPI 1083865257
$11,102.81
in general payments reported to CMS, 2019-2025
27 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $3,391 · 2023: $5,842 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,643 · Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,642.50 |
| Food and Beverage | $348.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,777.13 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $3,080.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $555.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $252.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $210.58 | 2019 | |
| Grifols USA, LLC | $150.41 | 2019 | |
| Mallinckrodt Hospital Products INC. | $131.73 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $124.78 | 2019 | |
| Emd Serono, INC. | $104.20 | 2019 | |
| Organon LLC | $93.48 | 2023 | |
| Ucb, INC. | $90.19 | 2019 | |
| Allergan, INC. | $80.23 | 2019 | |
| Avanir Pharmaceuticals, INC. | $57.50 | 2019 | |
| Acorda Therapeutics, INC | $50.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.93 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $39.44 | 2020 | |
| Csl Behring | $39.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.91 | 2020 | |
| Biogen, INC. | $24.49 | 2019 | |
| Chiesi USA, INC. | $24.35 | 2019-2020 | |
| Novocure INC. | $23.86 | 2019 | |
| Boston Scientific Corporation | $20.73 | 2019 | |
| Pfizer INC. | $20.00 | 2019 | |
| Ge Healthcare | $19.26 | 2019 | |
| Glaxosmithkline, LLC. | $17.71 | 2025 | Benlysta |
| Shire North American Group INC | $16.00 | 2019 | |
| Sk Life Science, INC. | $15.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.